ADC Therapeutics announced the shutdown of its UK research and development site along with a 30% workforce reduction, in a strategic move to concentrate resources on its approved monoclonal antibody and select preclinical programs. The restructuring follows clinical setbacks and portfolio prioritization, underscoring challenges faced by biopharma firms in maintaining diverse development pipelines amid financial and operational pressures.